Calbindin-D28k in the basal ganglia of patients with parkinsonism

Hidefumi Ito, Satoshi Goto, Shizuki Sakamoto, Asao Hirano

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

An immunohistochemical study was carried out to investigate the topographic distribution of Calbindin-D28k in the human basal ganglia and substantia nigra and its alterations in patients with idiopathic Parkinson's disease (PD), parkinsonism-dementia complex on Guam, progressive supranuclear palsy, and striatonigral degeneration. In normal control subjects, calbindin-D28k immunoreactivity was identified in the medium-sized neurons and neuropil of the matrix compartment of the striatum, the woolly fiber arrangements of the globus pallidus, and the fiber structures of the pars reticulata of the substantia nigra. Calbindin-D28k expression in the basal ganglia of patients with PD and parkinsonism-dementia on Guam was not different from that of control subjects, suggesting that the matrical output pathway is spared in these disorders. In contrast, its disruption is inferred from the observed disorganization of woolly fibers in the globus pallidus of patients with progressive supranuclear palsy and the reduced calbindin-D28k reactivity in the putaminal matrix and the pars reticulata of the substantia nigra of subjects with striatal degeneration. Thus, our results indicate that calbindin-D28k is a useful marker for the projection system from the matrix compartment and that its expression is modified in patients with progressive supranuclear palsy and striatal degeneration. Ito H, Goto S, Sakamoto S, Hirano A. Calbindin-D28k in the basal ganglia of patients with parkinsonism.

Original languageEnglish (US)
Pages (from-to)543-550
Number of pages8
JournalAnnals of Neurology
Volume32
Issue number4
StatePublished - Oct 1992

Fingerprint

Calbindin 1
Parkinsonian Disorders
Basal Ganglia
Progressive Supranuclear Palsy
Guam
Corpus Striatum
Globus Pallidus
Parkinson Disease
Dementia
Striatonigral Degeneration
Neuropil
Substantia Nigra
Neurons

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Ito, H., Goto, S., Sakamoto, S., & Hirano, A. (1992). Calbindin-D28k in the basal ganglia of patients with parkinsonism. Annals of Neurology, 32(4), 543-550.

Calbindin-D28k in the basal ganglia of patients with parkinsonism. / Ito, Hidefumi; Goto, Satoshi; Sakamoto, Shizuki; Hirano, Asao.

In: Annals of Neurology, Vol. 32, No. 4, 10.1992, p. 543-550.

Research output: Contribution to journalArticle

Ito, H, Goto, S, Sakamoto, S & Hirano, A 1992, 'Calbindin-D28k in the basal ganglia of patients with parkinsonism', Annals of Neurology, vol. 32, no. 4, pp. 543-550.
Ito H, Goto S, Sakamoto S, Hirano A. Calbindin-D28k in the basal ganglia of patients with parkinsonism. Annals of Neurology. 1992 Oct;32(4):543-550.
Ito, Hidefumi ; Goto, Satoshi ; Sakamoto, Shizuki ; Hirano, Asao. / Calbindin-D28k in the basal ganglia of patients with parkinsonism. In: Annals of Neurology. 1992 ; Vol. 32, No. 4. pp. 543-550.
@article{43f96dc28e3b44fdb4815efb38b12247,
title = "Calbindin-D28k in the basal ganglia of patients with parkinsonism",
abstract = "An immunohistochemical study was carried out to investigate the topographic distribution of Calbindin-D28k in the human basal ganglia and substantia nigra and its alterations in patients with idiopathic Parkinson's disease (PD), parkinsonism-dementia complex on Guam, progressive supranuclear palsy, and striatonigral degeneration. In normal control subjects, calbindin-D28k immunoreactivity was identified in the medium-sized neurons and neuropil of the matrix compartment of the striatum, the woolly fiber arrangements of the globus pallidus, and the fiber structures of the pars reticulata of the substantia nigra. Calbindin-D28k expression in the basal ganglia of patients with PD and parkinsonism-dementia on Guam was not different from that of control subjects, suggesting that the matrical output pathway is spared in these disorders. In contrast, its disruption is inferred from the observed disorganization of woolly fibers in the globus pallidus of patients with progressive supranuclear palsy and the reduced calbindin-D28k reactivity in the putaminal matrix and the pars reticulata of the substantia nigra of subjects with striatal degeneration. Thus, our results indicate that calbindin-D28k is a useful marker for the projection system from the matrix compartment and that its expression is modified in patients with progressive supranuclear palsy and striatal degeneration. Ito H, Goto S, Sakamoto S, Hirano A. Calbindin-D28k in the basal ganglia of patients with parkinsonism.",
author = "Hidefumi Ito and Satoshi Goto and Shizuki Sakamoto and Asao Hirano",
year = "1992",
month = "10",
language = "English (US)",
volume = "32",
pages = "543--550",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Calbindin-D28k in the basal ganglia of patients with parkinsonism

AU - Ito, Hidefumi

AU - Goto, Satoshi

AU - Sakamoto, Shizuki

AU - Hirano, Asao

PY - 1992/10

Y1 - 1992/10

N2 - An immunohistochemical study was carried out to investigate the topographic distribution of Calbindin-D28k in the human basal ganglia and substantia nigra and its alterations in patients with idiopathic Parkinson's disease (PD), parkinsonism-dementia complex on Guam, progressive supranuclear palsy, and striatonigral degeneration. In normal control subjects, calbindin-D28k immunoreactivity was identified in the medium-sized neurons and neuropil of the matrix compartment of the striatum, the woolly fiber arrangements of the globus pallidus, and the fiber structures of the pars reticulata of the substantia nigra. Calbindin-D28k expression in the basal ganglia of patients with PD and parkinsonism-dementia on Guam was not different from that of control subjects, suggesting that the matrical output pathway is spared in these disorders. In contrast, its disruption is inferred from the observed disorganization of woolly fibers in the globus pallidus of patients with progressive supranuclear palsy and the reduced calbindin-D28k reactivity in the putaminal matrix and the pars reticulata of the substantia nigra of subjects with striatal degeneration. Thus, our results indicate that calbindin-D28k is a useful marker for the projection system from the matrix compartment and that its expression is modified in patients with progressive supranuclear palsy and striatal degeneration. Ito H, Goto S, Sakamoto S, Hirano A. Calbindin-D28k in the basal ganglia of patients with parkinsonism.

AB - An immunohistochemical study was carried out to investigate the topographic distribution of Calbindin-D28k in the human basal ganglia and substantia nigra and its alterations in patients with idiopathic Parkinson's disease (PD), parkinsonism-dementia complex on Guam, progressive supranuclear palsy, and striatonigral degeneration. In normal control subjects, calbindin-D28k immunoreactivity was identified in the medium-sized neurons and neuropil of the matrix compartment of the striatum, the woolly fiber arrangements of the globus pallidus, and the fiber structures of the pars reticulata of the substantia nigra. Calbindin-D28k expression in the basal ganglia of patients with PD and parkinsonism-dementia on Guam was not different from that of control subjects, suggesting that the matrical output pathway is spared in these disorders. In contrast, its disruption is inferred from the observed disorganization of woolly fibers in the globus pallidus of patients with progressive supranuclear palsy and the reduced calbindin-D28k reactivity in the putaminal matrix and the pars reticulata of the substantia nigra of subjects with striatal degeneration. Thus, our results indicate that calbindin-D28k is a useful marker for the projection system from the matrix compartment and that its expression is modified in patients with progressive supranuclear palsy and striatal degeneration. Ito H, Goto S, Sakamoto S, Hirano A. Calbindin-D28k in the basal ganglia of patients with parkinsonism.

UR - http://www.scopus.com/inward/record.url?scp=0026616873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026616873&partnerID=8YFLogxK

M3 - Article

C2 - 1456738

AN - SCOPUS:0026616873

VL - 32

SP - 543

EP - 550

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 4

ER -